title: Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency.
abstract: The safety of gadolinium (Gd-benzyloxypropionictetra-acetate [BOPTA] dimeglumine) infusion was evaluated in 32 patients with severe or moderate chronic renal failure in a prospective, randomized, double-blind, placebo-controlled study. Renal failure was defined as severe if creatinine clearance was between 10 and 29 mL/min, and as moderate if creatinine clearance was between 30 and 60 mL/min. Serum creatinine level and 24-hour urine samples for creatinine clearance were followed up serially for 7 days after the administration of either gadolinium (Gd-BOPTA dimeglumine), 0.2 mmol/kg, or a saline infusion. No patient experienced a significant change in renal function, defined as an increase in serum creatinine level greater than 0.5 mg/dL more than baseline, and no patient required hospitalization or dialysis during the study period. Gadolinium (Gd-BOPTA dimeglumine) appears to be well tolerated in patients with moderate to severe renal failure.
authors.affiliation: University of Pennsylvania, Philadelphia, PA 19104, USA. townsend@mail.med.upenn.edu
authors.forename: R R
authors.initials: RR
authors.lastname: Townsend
authors.forename: D L
authors.initials: DL
authors.lastname: Cohen
authors.forename: R
authors.initials: R
authors.lastname: Katholi
authors.forename: S K
authors.initials: SK
authors.lastname: Swan
authors.forename: B E
authors.initials: BE
authors.lastname: Davies
authors.forename: K
authors.initials: K
authors.lastname: Bensel
authors.forename: L
authors.initials: L
authors.lastname: Lambrecht
authors.forename: J
authors.initials: J
authors.lastname: Parker
mesh_terms: D003287:Contrast Media; D004311:Double-Blind Method; D005682:Gadolinium; D006801:Humans; D007262:Infusions, Intravenous; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000097:blood / Q000150:complications*
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D005682:Gadolinium